Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Schafer

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Microvascular Research|March 31, 2005
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitroKeith Dredge, Rebecca Horsfall, Simon P Robinson, et al.
Cancer Immunology, Immunotherapy : CII|November 15, 2008
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cellsChristine Galustian, Brendan Meyer, Marie-Christine Labarthe, et al.
Heart (British Cardiac Society)|August 1, 2025
Subphenogroups of acute heart failure with preserved ejection fraction: comprehensive proteomics and pathway analysisYohei Sotomi, Yuki Matsuoka, Christina Ebert, et al.
Clinical Pharmacology in Drug Development|June 28, 2023
Safety, Pharmacokinetics, and Antifibrotic Activity of CC-90001 (BMS-986360), a c-Jun N-Terminal Kinase Inhibitor, in Pulmonary FibrosisGerald Horan, Ying Ye, Mary Adams, et al.
RMD Open|December 30, 2022
Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritisChun Wu, Yanhua Hu, Peter Schafer, et al.
Journal of Medicinal Chemistry|March 5, 2009
Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitorHon-Wah Man, Peter Schafer, Lu Min Wong, et al.
Annals of the Rheumatic Diseases|July 9, 2026
A head-to-head comparison of abatacept and adalimumab in adults with early and dual seropositive rheumatoid arthritis plus HLA-DRB1 shared epitope: results from the randomised phase 3 AMPLIFIED trialPaul Emery, Michael E Weinblatt, Vivian P Bykerk, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 24, 2026
Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritisJinqi Liu, Yicong Li, Kai Fu, et al.
Journal of Medicinal Chemistry|April 21, 2017
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and AiolosMary E Matyskiela, Weihong Zhang, Hon-Wah Man, et al.
JACC. Basic to Translational Science|March 5, 2021
Quantitative Proteomic Analysis of Diabetes Mellitus in Heart Failure With Preserved Ejection FractionThomas C Hanff, Jordana B Cohen, Lei Zhao, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Microvascular Research|March 31, 2005
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitroKeith Dredge, Rebecca Horsfall, Simon P Robinson, et al.
Cancer Immunology, Immunotherapy : CII|November 15, 2008
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cellsChristine Galustian, Brendan Meyer, Marie-Christine Labarthe, et al.
Heart (British Cardiac Society)|August 1, 2025
Subphenogroups of acute heart failure with preserved ejection fraction: comprehensive proteomics and pathway analysisYohei Sotomi, Yuki Matsuoka, Christina Ebert, et al.
Clinical Pharmacology in Drug Development|June 28, 2023
Safety, Pharmacokinetics, and Antifibrotic Activity of CC-90001 (BMS-986360), a c-Jun N-Terminal Kinase Inhibitor, in Pulmonary FibrosisGerald Horan, Ying Ye, Mary Adams, et al.
RMD Open|December 30, 2022
Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritisChun Wu, Yanhua Hu, Peter Schafer, et al.
Journal of Medicinal Chemistry|March 5, 2009
Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitorHon-Wah Man, Peter Schafer, Lu Min Wong, et al.
Annals of the Rheumatic Diseases|July 9, 2026
A head-to-head comparison of abatacept and adalimumab in adults with early and dual seropositive rheumatoid arthritis plus HLA-DRB1 shared epitope: results from the randomised phase 3 AMPLIFIED trialPaul Emery, Michael E Weinblatt, Vivian P Bykerk, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 24, 2026
Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritisJinqi Liu, Yicong Li, Kai Fu, et al.
Journal of Medicinal Chemistry|April 21, 2017
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and AiolosMary E Matyskiela, Weihong Zhang, Hon-Wah Man, et al.
JACC. Basic to Translational Science|March 5, 2021
Quantitative Proteomic Analysis of Diabetes Mellitus in Heart Failure With Preserved Ejection FractionThomas C Hanff, Jordana B Cohen, Lei Zhao, et al.
Pageof 6